報價延遲最少15分鐘:2024/05/15 01:39 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
147.89 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.52/-1.56
|
|
企業價值
20.22B
|
| 資產負債 |
|
每股賬面淨值
-1.73
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
1.83B
|
|
每股收益
13.63
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/15 01:39 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |